Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.

Background: It is still controversial if activating mutations in the stimulatory G-protein α subunit ( mutation) are a biomarker of response to first generation somatostatin receptor ligands (fg-SRL) treatment in acromegaly. Thus, we aimed to evaluate whether mutation predicts long-term response to fg-SRL treatment and to characterize the phenotype of patients harboring mutations.

Methods: sequencing was performed by Sanger.

Brazilian multicenter study on pegvisomant treatment in acromegaly.

Objective: Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a real-life, Brazilian multicenter study.

Subjects And Methods: Characteristics of acromegaly patients treated with PEGV were reviewed at diagnosis, just before and during treatment. All patients with at least two IGF-I measurements on PEGV were included.